Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy

Abstract

Aβ immunotherapy for Alzheimer's disease (AD) results in the removal of Av plaques and increased cerebral amyloid angiopathy (CAA). In current clinical trials, amyloid-related imaging abnormalities (ARIAs), putatively due to exacerbation of CAA, are concerning side effects. We aimed to assess the role of the Aβ transporter apolipoprotein E (apoE) in the exacerbation of CAA and development of CAA-associated vasculopathy after Aβ immunotherapy. 12 Aβ42-immunized AD (iAD; AN1792, Elan Pharmaceuticals) cases were compared with 28 unimmunized AD (cAD) cases. Immunohistochemistry was quantified for Aβ42, apoE, apoE E4 and smooth muscle actin, and CAA-associated vasculopathy was analyzed. Aβ immunotherapy was associated with redistribution of apoE from cortical plaques to cerebral vessel walls, mirroring the altered distribution of Aβ42. Concentric vessel wall splitting was increased threefold in leptomeningeal vessels after immunotherapy (cAD 6.3 vs iAD 20.6 %, P < 0.001), but smooth muscle cell abnormalities did not differ. The findings suggest that apoE is involved in the removal of plaques and transport of Aβ to the cerebral vasculature induced by Aβ immunotherapy. Immunotherapy was not associated with CAA-related vascular smooth muscle damage, but was accompanied by increased splitting of the vessel wall, perhaps reflecting enhanced deposition and subsequent removal of Aβ. ARIA occurring in some current trials of Aβ immunotherapy may reflect an extreme form of these vascular changes

More information

Identifiers

ORCID for Delphine Boche: orcid.org/0000-0002-5884-130X

ORCID for Roxana Carare: orcid.org/0000-0001-6458-3776

ORCID for David Johnston: orcid.org/0000-0001-6703-6014

ORCID for Clive Holmes: orcid.org/0000-0003-1999-6912

ORCID for James A R Nicoll: orcid.org/0000-0002-9444-7246

Catalogue record

Export record

Altmetrics